BioXcel Therapeutics (BTAI) Misses Q1 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 12, 2020 7:00 AM EDTÂ Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020
The Company is assessing data for dose escalation in the TRANQUILITY study and is on track to report results in mid-2020
Recommended Phase 2 dose of BXCL701 identified for combination study with KEYTRUDA®, leading to the initiation of the Phase 2 efficacy trial for advanced prostate cancer
Strengthened balance sheet through follow-on offering raising approximately $60 million in net proceeds
NEW HAVEN, Conn., May 12, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq:... More
